Recently added Catalysts

CGTX Positive Sentiment

Episode 6: Geographic Atrophy – New Strategies to Protect the Retina

Thursday, September 7, 2023 BiopharmaWatch Research 1 min read

Key Takeaway: The episode features discussions on new strategies to protect the retina from geographic atrophy, highlighting advances in understanding the condition. Experts share insights on the role of complement in dry AMD and evidence supporting sigma-2 modulation. The MAGNIFY Trial is also mentioned as part of the ongoing research.

Price reaction · baseline $1.52 (2023-09-06 close) · hit after-hours · 1 other CGTX headline(s) in the window, move may be shared

day 0 close

+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

Innovative strategies discussed for protecting the retina.
Expert insights from leading ophthalmology professionals.
Focus on advances in understanding geographic atrophy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice

Best trade, last catalyst

+35%

120-day peak, hindsight

Typical move

8.3%

average across 6 past catalysts

Cash runway

~33 mo

Minimal dilution risk

Lead asset

Oxytocin

Phase 2 · Oxidative Stress

Full Press Release Details

Episode 6: Geographic Atrophy – New Strategies to Protect the Retina

Featuring:

Anthony Caggiano, M.D., Ph.D.

Cognition Therapeutics

Chief Medical Officer

C. Gustavo De Moraes, M.D., Ph.D.

moderator

Columbia University and Ora (CRO)

Associate Professor of Clinical Ophthalmology

Chief Medical Officer

Jeffrey S. Heier, M.D.

Ophthalmic Consultants of Boston

Director of the Vitreoretinal Service & Retina Research

Peter K. Kaiser, M.D.

Cleveland Clinic Lerner College of Medicine

Chaney Family Endowed Chair in Ophthalmology Research

and Professor of Ophthalmology

Index: